Trump Administration Initiates Cannabis Reclassification and Tax Relief

The Trump administration announced a two-part policy change affecting the legal cannabis sector. First, federal controls on medical marijuana were relaxed, moving the product from the Schedule I category of highly addictive substances to a lower-risk schedule overseen by the Drug Enforcement Administration, akin to prescription analgesics. Second, the administration launched a broader reclassification process that could extend the new schedule to recreational cannabis. The changes aim to reduce regulatory burdens and stimulate investment in the industry.

New York Times

The legal cannabis market has expanded to roughly $30 billion, up from under $20 billion six years earlier. Despite growth, investors remain cautious because effective tax rates—approximately 70 percent—are double those of most other businesses, and cannabis remains illegal under federal law. Companies must pay taxes on gross income rather than net profit, limiting deductions for expenses such as rent and payroll.

New York Times

Reclassifying cannabis could halve the sector’s tax burden; under the proposed schedule, licensed medical marijuana sellers would be eligible for standard business deductions, and a similar framework would apply to recreational sellers. The Treasury is evaluating retroactive application of the relief, potentially affecting taxes owed for prior years. In 2025, legal cannabis firms owed $2.24 billion to the Internal Revenue Service, per Whitney Economics. Publicly traded entities—including Trulieve, Florida’s largest medical cannabis company, and Curaleaf, a New York-based multinational—reported combined federal tax liabilities exceeding $1.6 billion.

New York Times

The Treasury is considering making the tax relief retroactive but has not issued formal guidance. The Internal Revenue Service has not issued guidance on the new classification’s mechanics. Meanwhile, the Drug Enforcement Administration has begun permitting cannabis businesses to register under the revised schedule, marking the first step toward broader regulatory change.

New York Times

Stakeholders caution that the lack of detailed guidance creates uncertainty about the benefits of reclassification. Questions remain on how firms operating both medical and recreational lines will be treated under the new tax framework. Without clear rules, the anticipated reduction in tax liabilities may not materialize uniformly across the sector.

New York Times

Sources differ on the timeline for Treasury and IRS rulemaking, and no definitive schedule for the broader reclassification has been announced. The absence of concrete guidance leaves a gap in understanding how the policy will apply to mixed-model operators and whether retroactive relief will be granted.

New York Times

The administration’s reclassification effort could reshape the fiscal environment for cannabis businesses, pending regulatory guidance from the Treasury, IRS, and DEA. Industry observers will monitor forthcoming rulebooks to assess the impact on tax obligations and investment flows.

New York Times